Under one in 10 individuals that would benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it publishes its first advice on the drugs.
Considering more than one billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 without intervention.
"Our latest guidelines recognises that obesity is a lifelong illness that can be managed with comprehensive and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key hurdles to broad availability to the injections that can assist patients in reducing significant body mass, explains the body.
Weight-Loss Drug Scarcity
Even in the current most optimistic case, the production of such drugs could only cover around 100 million people – under 10% of those who need them, per the WHO.
The advice calls on nations and manufacturers to increase availability, by approaches such as voluntary licensing.
The intellectual property rights on semaglutide – the primary component of a leading brand – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so individuals consume fewer calories.
People usually start to lose weight in the initial weeks of beginning the once-weekly jabs.
Research suggests users may see weight return within a year of stopping the drug, because their normal appetite come back.
To be above a healthy weight elevates your likelihood for contracting diseases, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight impacts people in every country and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
